Table 3.
Outcome of treatment with donor virus‐specific T cells (VSTs) in our studies
| Specificity | Virus | Patients | Partial or complete response | Failure | References |
|---|---|---|---|---|---|
| Monovirus VSTs with prolonged culture | |||||
| LCL‐induced EBV VSTs | EBV | 13 | 11 | 2 |
Rooney et al. 80 Heslop et al. 79 Rooney et al. 81 Heslop et al. 22 |
| Bivirus VSTs with prolonged culture | |||||
| AD5/35 induced EBV/ADV VSTs | EBV | 1 | 1 | 0 | Leen et al. 101 |
| AdV | 2 | 1 | 1 | ||
| Trivirus VSTs with prolonged culture | |||||
| AD5/35 pp65 induced CMV/ADV/EBV VSTs | EBV | 6 | 6 | 0 | Leen et al. 102 |
| AdV | 6 | 5 | 1 | ||
| CMV | 11 | 10 | 1 | ||
| Trivirus VSTs with rapid culture | |||||
| Plasmid induced CMV/ADV/EBV VSTs | EBV | 2 | 2 | 0 | Gerdemann et al. 112 |
| AdV | 4 | 4 | 0 | ||
| CMV | 5 | 4 | 1 | ||
| Total | EBV | 22 | 20 | 2 | |
| AdV | 12 | 10 | 2 | ||
| CMV | 16 | 14 | 2 | ||
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.